Clinical Trial

Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors

Name: Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors — clinical trial record (NCT07231081)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a single-arm, open-label, Phase I study to evaluate the safety, tolerability, and antitumor activity of TX103 CAR-T cells in subjects with TX103-positive advanced solid tumors. The study also aims to explore the maximum tolerated dose (MTD) and determine the recommended Phase II dose (RP2D) of TX103 CAR-T cell therapy.

Trial Details

NCT Number	NCT07231081
Lead Sponsor	Tcelltech Inc.
Conditions	Solid Tumors
Enrollment	85 participants
Start Date	2025-10-16
Primary Completion	2027-12-20 (estimated)
Study Completion	2027-12-20 (estimated)
Updated on ClinicalTrials.gov	2025-11-17